Post job

Chromocell main competitors are Retrophin, Promega, and Cerecor.

Competitor Summary. See how Chromocell compares to its main competitors:

  • Carondelet Health Network has the most employees (5,218).
  • Employees at Retrophin earn more than most of the competitors, with an average yearly salary of $101,141.
Work at Chromocell?
Share your experience

Chromocell vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
2002
4.4
North Brunswick, NJ1$32.5M214
2017
4.0
Boulder, CO1$30,00045
2011
3.8
San Diego, CA1$198.3M262
2011
4.2
Baltimore, MD2$6.7M32
1978
4.7
Madison, WI2$450.0M1,601
1992
4.5
Needham, MA1$70.0M111
1988
3.6
Lenoir City, TN1$29.3M225
-
4.1
Denver, CO1$11.0M158
-
3.9
San Diego, CA1$49.9M690
1880
4.6
Tucson, AZ3$830.0M5,218
2006
3.7
Cambridge, MA1-59
1999
3.7
Piscataway, NJ1$8.5M150
1999
4.1
South Plainfield, NJ1$45.4M100
1986
4.1
Asheville, NC2$78.0M519

Rate Chromocell's competitiveness in the market.

Zippia waving zebra

Chromocell salaries vs competitors

Among Chromocell competitors, employees at Retrophin earn the most with an average yearly salary of $101,141.

Compare Chromocell salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Chromocell
$51,660$24.84-
Edgewise Therapeutics
$50,648$24.35-
Retrophin
$101,141$48.63-
Cerecor
$67,371$32.39-
Promega
$72,593$34.90-
Cambridge Healthtech Institute
$64,417$30.97-

Compare Chromocell job title salaries vs competitors

CompanyHighest salaryHourly salary
Chromocell
$71,863$34.55
Promega
$87,297$41.97
Genocea
$84,023$40.40
GENEWIZ
$83,483$40.14
MicroConstants
$81,133$39.01
Edgewise Therapeutics
$75,071$36.09
Cerecor
$72,736$34.97
Forensic Laboratories
$70,532$33.91
RUCDR
$70,365$33.83
Cambridge Healthtech Institute
$69,161$33.25
Genova Diagnostics
$69,022$33.18
Carondelet Health Network
$68,901$33.13
Fort Loudoun Medical Center
$68,762$33.06
Retrophin
$68,038$32.71

Do you work at Chromocell?

Is Chromocell able to compete effectively with similar companies?

Chromocell jobs

Chromocell demographics vs competitors

Compare gender at Chromocell vs competitors

Job titleMaleFemale
Carondelet Health Network29%71%
Genova Diagnostics35%65%
MicroConstants46%54%
GENEWIZ55%45%
Chromocell--
Male
Female
100%
75%
50%
25%
0%
0%
25%
50%
75%
100%

Compare race at Chromocell vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
57%28%5%6%5%
9.3
57%10%22%8%3%
7.7
43%31%6%18%3%
7.7
44%12%8%32%4%
8.2

Chromocell and similar companies CEOs

CEOBio
Michael Cola
Cerecor

Michael Cola joined Medgenics as President and CEO in September 2013. Prior to joining Medgenics, Mr. Cola served as President of Specialty Pharmaceuticals at Shire plc, a global specialty pharmaceutical company, from 2007 until April 2012. He joined Shire in 2005 as EVP of Global Therapeutic Business Units and Portfolio Management. Prior to joining Shire, he was with Safeguard Scientifics, Inc., a growth capital provider to life sciences and technology companies, where he served as President of the Life Sciences Group. While at Safeguard, Mr. Cola served as Chairman and CEO of Clarient, Inc., a cancer diagnostics company subsequently acquired by GE Healthcare, and as Chairman of Laureate Pharma, Inc., a full-service contract manufacturing organization serving research-based biologics companies. Prior to Safeguard Scientifics, Mr. Cola held senior positions in product development and commercialization at AstraMerck, a top 20 U.S. pharmaceutical company, and at AstraZeneca, a global biopharmaceutical company. Mr. Cola received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. He serves on the Board of Directors of Vanda Pharmaceuticals Inc., Sage Therapeutics, Ben Franklin Technology Partners and Pennsylvania BIO, the statewide association representing the bioscience community. He also currently serves as Chairman of the Board of Governors of the Boys & Girls Clubs of Philadelphia.

Chip Clark
Genocea

Prior to joining Genocea,Chip co-founded and served as Chief Business Officer of Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Before that, Chip was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial roles at SmithKline Beecham (now GlaxoSmithKline). Chip holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.

An impressive healthcare executive and trusted advisor with a record of providing strategic long-term financial planning and leadership. Driving successful physician collaboration, clinical integration, acute care operations, Board relations, community inclusion in policy development, and shared services for healthcare operations. Influencing critical decisions and lead high-level insight on strategic initiatives, consolidation, and revitalization for healthcare organizations. Assess resources and technology barriers then implement million-dollar revenue enhancements while reducing costs.

Jeffrey Ledford
Genova Diagnostics

Steve Sun
GENEWIZ

Robin Grimwood
RUCDR

Chromocell competitors FAQs

Search for jobs